Nicotinamide Riboside Supply Agreement between Thorne Research, Inc. & Chromadex, Inc. Nicotinamide Riboside-Choline and/or BetaineNicotinamide Riboside Supply Agreement • November 10th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products
Seller Chromadex, Inc. Buyer Thorne Research, Inc. Product Nicotinamide Riboside Chloride (Product Specification attached hereto) Term As defined by the NIAGEN® SUPPLY AGREEMENT, dated July 9, 2013 (“Original Agreement”) Intent 1) To add Choline and/or Betaine and/or dimethylglycine (DMG) to the Original Agreement (hereinafter the NR-Choline-Betaine-DMG Combination Product) 2) To permit Buyer the sole rights to the Combination of Nicotinamide Riboside (NR) with Choline and/or Betaine and/or DMG (all forms) 3) To permit Buyer the right to engage in the research, advertising, promotion, manufacturing, packaging, shipment, distribution, use, offer for sale, and sale of the NR-Choline-Betaine-DMG Combination Product or of Derivatives of the NR-Choline-Betaine-DMG Combination Product 4) Derivatives of the NR-Choline-Betaine-DMG Combination Product are defined as any product that contains the NR-Choline-Betaine-DMG Combination in combination with any other ingredient(s)
Second Addendum to Nicotinamide Riboside Supply Agreement between Thorne Research, Inc. & ChromaDex, Inc. Nicotinamide Riboside-Choline and/or BetaineNicotinamide Riboside Supply Agreement • November 10th, 2016 • ChromaDex Corp. • Medicinal chemicals & botanical products
Seller ChromaDex, Inc. Buyer Thorne Research, Inc. Effective Date September 14, 2016 Intent of Second Addendum 1) To extend the Term of the NIAGEN® SUPPLY AGREEMENT, dated July 9, 2013 (“Original Agreement”) between the parties. 2) To amend in the entirety, the Territory, the Exclusivity in the Territory, and the Exclusivity Requirements in the Original Agreement and in the Addendum to the Nicotinamide Riboside Supply Agreement, dated July 24, 2015 (“Addendum”). Term October 1, 2016 through December 31, 2018 Territory and Exclusivity in the Territory (amended) 1) Thorne retains exclusivity for stand-alone NR in the Licensed Health Care Professionals Channel in the United States only. 2) Thorne retains exclusive rights to the combination of Nicotinamide Riboside (NR) with Choline and/or Betaine and/or DMG (all forms) (“Combination Product”) in all channels, in the United States and Canada, with right of first refusal for other countries. 3) Thorne obtains exclusive rights to the combina
